A Review of Psma-Based Radiopharmaceuticals for Diagnosis and Therapy of Prostate Cancer

A Review of Psma-Based Radiopharmaceuticals for Diagnosis and Therapy of Prostate Cancer Publisher

Farbod A ; Farzanehfar S ; Beheshti M ; Delpassand ES ; Hashmi MJ ; Aghanejad A ; Eppard E ; Vahidfar N

Source: Journal of Radioanalytical and Nuclear Chemistry Published:2025

Abstract

During the last decade, diagnosis and therapy of prostate cancer have been accomplished with clear evidence of enhanced survival. Improved diagnostic capabilities, particularly radiolabeled PSMA PET/CT approaches benefit from reduced unnecessary biopsies and more accuracy. The advantage of visualization of the abnormalities prior to therapeutic procedures is clarifying these locations specifically in order to targeting therapy applying the theranostic principle. Targeted therapy with high efficacy and minimal damage has emerged as very promising advancement in nuclear medicine. Recently, radiolabeled PSMA-617 and other derivatives have shown considerable improvements in the management of advanced-stage PSMA–positive mCRPC. This manuscript attempts to summarize the most recent advancements in the diagnosis and treatment of prostate cancer in nuclear medicine. © 2025 Elsevier B.V., All rights reserved.

Style	Citing Format
MLA	Farbod A, et al.. "A Review of Psma-Based Radiopharmaceuticals for Diagnosis and Therapy of Prostate Cancer." Journal of Radioanalytical and Nuclear Chemistry, vol. 334, no. 10, 2025, pp. 6889-6897.
APA	Farbod A, Farzanehfar S, Beheshti M, Delpassand ES, Hashmi MJ, Aghanejad A, Eppard E, Vahidfar N (2025). A Review of Psma-Based Radiopharmaceuticals for Diagnosis and Therapy of Prostate Cancer. Journal of Radioanalytical and Nuclear Chemistry, 334(10), 6889-6897.
Chicago	Farbod A, Farzanehfar S, Beheshti M, Delpassand ES, Hashmi MJ, Aghanejad A, Eppard E, Vahidfar N. "A Review of Psma-Based Radiopharmaceuticals for Diagnosis and Therapy of Prostate Cancer." Journal of Radioanalytical and Nuclear Chemistry 334, no. 10 (2025): 6889-6897.
Harvard	Farbod A et al. (2025) 'A Review of Psma-Based Radiopharmaceuticals for Diagnosis and Therapy of Prostate Cancer', Journal of Radioanalytical and Nuclear Chemistry, 334(10), pp. 6889-6897.
Vancouver	Farbod A, Farzanehfar S, Beheshti M, Delpassand ES, Hashmi MJ, Aghanejad A, et al.. A Review of Psma-Based Radiopharmaceuticals for Diagnosis and Therapy of Prostate Cancer. Journal of Radioanalytical and Nuclear Chemistry. 2025;334(10):6889-6897.
BibTex	@article{ author = {Farbod A and Farzanehfar S and Beheshti M and Delpassand ES and Hashmi MJ and Aghanejad A and Eppard E and Vahidfar N}, title = {A Review of Psma-Based Radiopharmaceuticals for Diagnosis and Therapy of Prostate Cancer}, journal = {Journal of Radioanalytical and Nuclear Chemistry}, volume = {334}, number = {10}, pages = {6889-6897}, year = {2025} }
RIS	TY - JOUR AU - Farbod A AU - Farzanehfar S AU - Beheshti M AU - Delpassand ES AU - Hashmi MJ AU - Aghanejad A AU - Eppard E AU - Vahidfar N TI - A Review of Psma-Based Radiopharmaceuticals for Diagnosis and Therapy of Prostate Cancer JO - Journal of Radioanalytical and Nuclear Chemistry VL - 334 IS - 10 SP - 6889 EP - 6897 PY - 2025 ER -

Science Communicator Platform

Authors

Abstract